Versatope Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Versatope Therapeutics's estimated annual revenue is currently $2.8M per year.
- Versatope Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Versatope Therapeutics has 18 Employees.
- Versatope Therapeutics grew their employee count by 6% last year.
Versatope Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO/Co-Founder | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | VP, Head Research and Development | Reveal Email/Phone |
4 | SVP Portfolio Management & Preclinical Development | Reveal Email/Phone |
5 | Project and Alliance Manager | Reveal Email/Phone |
6 | Pharm Development and Analytical Scientist - Versatope Therapeutics | Reveal Email/Phone |
7 | Process Development Scientist | Reveal Email/Phone |
8 | Scientist I | Reveal Email/Phone |
Versatope Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Versatope Therapeutics?
Versatope Therapeutics is an infectious disease company with two lead development programs and others at the preclinical stage. Versatope delivers immunity by customizing nano-size vesicles by using synthetic biology for biopharmaceutical applications.
keywords:N/AN/A
Total Funding
18
Number of Employees
$2.8M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.8M | 19 | -34% | N/A |
#2 | $2M | 20 | 18% | N/A |
#3 | $3.2M | 21 | 5% | N/A |
#4 | N/A | 21 | -25% | N/A |
#5 | $4.3M | 23 | -15% | N/A |